- Home
- KIM vs PODD Comparison
KIM vs PODD Comparison
Compare KIM & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIM
- PODD
- Stock Information
- Founded
- KIM 1958
- PODD 2000
- Country
- KIM United States
- PODD United States
- Employees
- KIM N/A
- PODD N/A
- Industry
- KIM Real Estate Investment Trusts
- PODD Medical/Dental Instruments
- Sector
- KIM Real Estate
- PODD Health Care
- Exchange
- KIM Nasdaq
- PODD Nasdaq
- Market Cap
- KIM 14.4B
- PODD 19.0B
- IPO Year
- KIM 1991
- PODD 2007
- Fundamental
- Price
- KIM $20.13
- PODD $244.21
- Analyst Decision
- KIM Buy
- PODD Buy
- Analyst Count
- KIM 16
- PODD 17
- Target Price
- KIM $24.28
- PODD $294.65
- AVG Volume (30 Days)
- KIM 4.6M
- PODD 933.8K
- Earning Date
- KIM 05-01-2025
- PODD 05-08-2025
- Dividend Yield
- KIM 4.99%
- PODD N/A
- EPS Growth
- KIM N/A
- PODD 96.55
- EPS
- KIM 0.55
- PODD 5.78
- Revenue
- KIM $2,037,014,000.00
- PODD $2,071,600,000.00
- Revenue This Year
- KIM N/A
- PODD $20.58
- Revenue Next Year
- KIM $3.24
- PODD $17.41
- P/E Ratio
- KIM $36.45
- PODD $42.18
- Revenue Growth
- KIM 14.22
- PODD 22.07
- 52 Week Low
- KIM $17.57
- PODD $160.19
- 52 Week High
- KIM $25.83
- PODD $289.46
- Technical
- Relative Strength Index (RSI)
- KIM 28.94
- PODD 33.12
- Support Level
- KIM $20.44
- PODD $230.05
- Resistance Level
- KIM $21.79
- PODD $255.63
- Average True Range (ATR)
- KIM 0.53
- PODD 10.51
- MACD
- KIM -0.11
- PODD -3.48
- Stochastic Oscillator
- KIM 4.53
- PODD 22.76
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 569 shopping centers throughout major markets in the US, representing roughly 87 million square feet.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it world-wide.